French biotech company TxCell (Euronext Paris: TXCL) announced yesterday that it has entered into an exclusive option agreement with Yeda Research and Development Co, the technology transfer arm of the Weizmann Institute of Science in Rehovot, Israel.
Financial terms of the option and of the license were not disclosed.
Resulting from the exclusive option agreement, TxCell will gain exclusive access to a CAR-Treg patent for suppression of autoimmune and inflammatory diseases originated in the Weizmann Institute of Science laboratory of Zelig Eshhar.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze